TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Earnings & Estimates
NYSE:TAK - US8740602052 - ADR
15.29 USD
+0.14 (+0.92%)
15.29 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.027T 12.85% | 4.264T 5.87% | 4.582T 7.45% | 4.6T 0.40% | 4.638T 0.83% | 4.727T 1.91% | |
| EBITDA YoY % growth | 1.215T 7.68% | 1.159T -4.65% | 1.298T 12.05% | 1.222T -5.90% | 1.229T 0.60% | 1.28T 4.16% | |
| EBIT YoY % growth | 550.895B 0.99% | 430.787B -21.80% | 537.031B 24.66% | 401.98B -25.15% | 503.99B 25.38% | N/A | |
| Operating Margin | 13.68% | 10.10% | 11.72% | 8.74% | 10.87% | N/A | |
| EPS YoY % growth | 101.28 38.81% | 45.63 -54.95% | 33.87 -25.77% | 76.10 124.68% | 96.99 27.46% | 110.05 13.46% |
All data in JPY
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 22.40 -22.23% | 18.14 146.43% | 0.27 100.85% | 26.77 -31.95% |
| Revenue Q2Q % growth | 1.188T 1.03% | 1.179T 3.07% | 1.072T 1.80% | 1.167T 5.46% |
| EBITDA Q2Q % growth | 365.187B -36.21% | 371.333B -41.91% | 242.369B -67.15% | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in JPY
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2026 Q2Q % growth | 39.34 30.79% | 28.31 | 11.03 | 38.94% |
| Q4 2025 Q2Q % growth | -32.38 -3,151.24% | -27.64 | -4.74 | -17.13% |
| Q3 2025 Q2Q % growth | 7.36 -78.01% | 12.60 | -5.24 | -41.58% |
| Q2 2025 Q2Q % growth | 28.81 287.55% | 16.41 | 12.39 | 75.50% |
| Q1 2025 Q2Q % growth | 30.08 5.56% | 21.90 | 8.18 | 37.34% |
| Q4 2024 Q2Q % growth | -1.00 -110.03% | 0.39 | -1.38 | -357.78% |
| Q3 2024 Q2Q % growth | 33.49 -11.88% | 14.26 | 19.23 | 134.84% |
| Q2 2024 Q2Q % growth | -15.36 -177.99% | 18.23 | -33.59 | -184.23% |
| Q1 2024 Q2Q % growth | 28.49 -15.35% | 34.62 | -6.12 | -17.69% |
| Q4 2023 Q2Q % growth | 9.92 388.22% | 6.73 | 3.20 | 47.57% |
| Q3 2023 Q2Q % growth | 38.00 107.24% | 37.30 | 0.70 | 1.89% |
| Q2 2023 Q2Q % growth | 19.69 35.93% | 19.14 | 0.56 | 2.91% |
| Q1 2023 Q2Q % growth | 33.66 -22.76% | 35.59 | -1.93 | -5.43% |
| Q4 2022 Q2Q % growth | -3.44 -105.51% | 2.98 | -6.43 | -215.36% |
| Q3 2022 Q2Q % growth | 18.34 -37.36% | 25.31 | -6.97 | -27.54% |
| Q2 2022 Q2Q % growth | 14.49 1,229.27% | 23.67 | -9.18 | -38.79% |
| Q1 2022 Q2Q % growth | 43.58 66.19% | 33.68 | 9.90 | 29.40% |
| Q4 2021 Q2Q % growth | 62.47 11,362.22% | 23.98 | 38.49 | 160.51% |
| Q3 2021 Q2Q % growth | 29.27 886.43% | 21.71 | 7.56 | 34.83% |
| Q2 2021 Q2Q % growth | 1.09 -93.64% | 16.29 | -15.20 | -93.31% |
| Q1 2021 Q2Q % growth | 26.22 498.57% | 8.03 | 18.20 | 226.72% |
| Q4 2020 Q2Q % growth | 0.54 101.14% | -52.62 | 53.16 | 101.04% |
| Q3 2020 Q2Q % growth | 2.97 -87.75% | -15.14 | 18.11 | 119.60% |
| Q2 2020 Q2Q % growth | 17.14 -43.93% | -23.32 | 40.46 | 173.52% |
| Q1 2020 Q2Q % growth | -6.58 -113.27% | -21.77 | 15.19 | 69.77% |
| Q4 2019 Q2Q % growth | -47.75 | -39.85 | -7.89 | -19.81% |
| Q2 2019 Q2Q % growth | 30.57 | 18.81 | 11.76 | 62.53% |
| Q1 2019 Q2Q % growth | 49.57 | 34.67 | 14.90 | 42.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2026 Q2Q % growth | 1.107T -8.39% | 1.187T | -80.177B | -6.76% |
| Q4 2025 Q2Q % growth | 1.053T 0.24% | 1.076T | -22.558B | -2.10% |
| Q3 2025 Q2Q % growth | 1.144T 2.96% | 1.15T | -5.501B | -0.48% |
| Q2 2025 Q2Q % growth | 1.176T 12.75% | 1.106T | 70.201B | 6.35% |
| Q1 2025 Q2Q % growth | 1.208T 14.11% | 1.104T | 104.296B | 9.45% |
| Q4 2024 Q2Q % growth | 1.051T 9.91% | 916.958B | 133.911B | 14.60% |
| Q3 2024 Q2Q % growth | 1.111T 1.33% | 1.017T | 93.961B | 9.24% |
| Q2 2024 Q2Q % growth | 1.043T 4.07% | 1.009T | 33.671B | 3.34% |
| Q1 2024 Q2Q % growth | 1.059T 8.86% | 992.223B | 66.395B | 6.69% |
| Q4 2023 Q2Q % growth | 956.156B 9.49% | 966.415B | -10.259B | -1.06% |
| Q3 2023 Q2Q % growth | 1.097T 21.66% | 1.015T | 81.727B | 8.05% |
| Q2 2023 Q2Q % growth | 1.002T 18.64% | 962.035B | 40.272B | 4.19% |
| Q1 2023 Q2Q % growth | 972.465B 2.41% | 934.47B | 37.995B | 4.07% |
| Q4 2022 Q2Q % growth | 873.289B 13.37% | 847.458B | 25.831B | 3.05% |
| Q3 2022 Q2Q % growth | 901.294B 7.71% | 846.517B | 54.777B | 6.47% |
| Q2 2022 Q2Q % growth | 844.82B 7.08% | 825.266B | 19.554B | 2.37% |
| Q1 2022 Q2Q % growth | 949.603B 18.43% | 873.46B | 76.143B | 8.72% |
| Q4 2021 Q2Q % growth | 770.274B -0.19% | 791.881B | -21.607B | -2.73% |
| Q3 2021 Q2Q % growth | 836.753B -2.63% | 847.525B | -10.772B | -1.27% |
| Q2 2021 Q2Q % growth | 788.935B -2.73% | 840.261B | -51.326B | -6.11% |
| Q1 2021 Q2Q % growth | 801.85B -5.57% | 814.274B | -12.424B | -1.53% |
| Q4 2020 Q2Q % growth | 771.702B 7.60% | 802.131B | -30.429B | -3.79% |
| Q3 2020 Q2Q % growth | 859.317B 72.07% | 844.174B | 15.143B | 1.79% |
| Q2 2020 Q2Q % growth | 811.048B 88.28% | 822.735B | -11.687B | -1.42% |
| Q1 2020 Q2Q % growth | 849.121B 88.76% | 824.716B | 24.405B | 2.96% |
| Q4 2019 Q2Q % growth | 717.211B | 761.028B | -43.817B | -5.76% |
| Q2 2019 Q2Q % growth | 430.777B | 475.949B | -45.172B | -9.49% |
| Q1 2019 Q2Q % growth | 449.834B | 447.597B | 2.237B | 0.50% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 2.26% | N/A | 2.66% | 1.53% |
| Revenue | 1.1% | N/A | -0.07% | -0.6% |